None listed
Conditions
Interventions
None listed
Sponsors
Kangbuk Samsung Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who had common bile duct stones that can not be removed by conventional endoscopic techniques, with signs and symptoms of cholangitis such as biliary pain, jaundice, and fever
Exclusion criteria
Exclusion criteria: 1) refuse to participate in the study, 2) If the remaining life expectancy is less than 6 months, 3) Patients who had previously experienced side effects on Ursa medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of both the transverse and longitudinal diameters of the common bile duct stones and common bile duct diameter at 6 months after the initial endoscopic retrograde cholangiopanreatography;The rate of complete CBD stones removal at 6 months after the initial endoscopic retrograde cholangiopanreatography | — |
Secondary
| Measure | Time frame |
|---|---|
| The rate of immediate or late complications related to biliary stent placement or endoscopic stone removal;The rate of immediate or late complications related to biliary stent placement or endoscopic stone removal;The occurrence of significant adverse side effects from the administration of Ursodeoxycholic acid | — |
Countries
Korea, Republic of
Contacts
Public ContactNam Hee Kim
Kangbuk Samsung Medical Center
Outcome results
None listed